Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2005
05/03/2005CA2128215C Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
04/2005
04/28/2005WO2005038430A2 Viral fibers
04/28/2005WO2005038028A1 Poxvirus vector encoding retrovirus (eg hiv) and cytokine
04/28/2005WO2005037999A2 Treatment of cancer using antibodies to lrrc15
04/28/2005WO2005037868A2 Methods of treating nfat-related disorders
04/28/2005WO2005037867A1 ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
04/28/2005WO2005037855A2 T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same
04/28/2005WO2005037854A2 Immunogenic peptides
04/28/2005WO2005037320A2 Process for preparing polysaccharide-protein conjugate vaccines
04/28/2005WO2005037315A1 Therapeutic agent for mesothelioma
04/28/2005WO2005037313A2 Tissue repair by modulation of beta-1 integrin biological function
04/28/2005WO2005037312A2 Binding molecules for the extra-domain b of fibronectin, used for the detection of atherosclerotic plaques
04/28/2005WO2005037311A1 Pharmaceutical compositions for therapeutic use
04/28/2005WO2005037310A1 Hepatitis a, b-combined vaccine and its lyophilized preparation
04/28/2005WO2005037309A1 A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis
04/28/2005WO2005037293A1 Immunomodulating compositions and uses therefor
04/28/2005WO2005037261A1 Combination therapy for cancer
04/28/2005WO2005037235A2 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
04/28/2005WO2005037233A2 Listeria-based epha2 vaccines
04/28/2005WO2005037222A2 Recombinant intracellular pathogen immunogenic compositions and methods for use
04/28/2005WO2005037206A2 Anti-cancer compounds and methods of use thereof
04/28/2005WO2005037205A2 Haloacetamide and azide substituted compounds and methods of use thereof
04/28/2005WO2005037194A2 Collagen interactions with prostate cancer cells
04/28/2005WO2005037190A2 Multiplex vaccines
04/28/2005WO2005024061A3 Compounds and methods for modulation of dna replication
04/28/2005WO2005019431A3 Selective inhibition of toll-like receptor-2
04/28/2005WO2005019266A3 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
04/28/2005WO2005014040A3 Antigen delivery system
04/28/2005WO2005013889A3 Truncated fragments of alpha-synuclein in lewy body disease
04/28/2005WO2005005481A3 Combination therapy for gastroenteric diseases caused by microorganisms
04/28/2005WO2004110390A3 Anti-cd74 immunoconjugates and methods
04/28/2005WO2004110250A3 Diagnostic method for atherosclerosis
04/28/2005WO2004075988A3 Methods of immunomodulation in animals
04/28/2005WO2004064784A3 Composition and method for preventing or treating a virus infection
04/28/2005WO2004064759A3 Use of tryptanthrin compounds for immune potentiation
04/28/2005WO2004060396A3 Immunogenic compositions containing phospholpid
04/28/2005WO2004049907A3 Compositions and methods for treating transplants
04/28/2005WO2004041846A3 INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES
04/28/2005WO2004032839A3 Methods and formulations comprising agonists and antagonists of nuclear hormone receptors
04/28/2005WO2004032622A3 Production of peptides in plants as viral coat protein fusions
04/28/2005WO2004011486A8 Method for solubilizing hydrophobic peptides and use thereof for inducing an antitumoral and/or anti-infectious ctl response
04/28/2005WO2004003161A3 Immunogenic mycoplasma hyopneumoniae polypeptides
04/28/2005WO2003095971A3 Posh nucleic acids, polypeptides and related methods
04/28/2005WO2003087389A3 Biologic modulations with nanoparticles
04/28/2005WO2003044170A3 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
04/28/2005WO2002072013A8 Method of treating malignancies through induction of blood immune responses
04/28/2005US20050090656 Cloning, sequencing and expresssion of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
04/28/2005US20050090646 cytotoxic fusion proteins that are useful for selectively killing endothelial cells in blood vessels that feed tumors
04/28/2005US20050090643 protein isolated from cyanobacteria, is known to have anti-viral activity
04/28/2005US20050090466 Inhibitors of PACE4 for the treatment of arthritis
04/28/2005US20050090441 inducing prolonged in vivo gene expression in mammal by contacting nonmuscular tissue with a nucleic acid, a histone, and an amphipathic compound; animal models:
04/28/2005US20050090440 Tumour treating combinations, compositions and methods
04/28/2005US20050090439 Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
04/28/2005US20050090435 nucleotide sequences, genetic vectors comprising and/or genes expressing the nucleotide sequences, use to transform plant cells to produce proteins or fragments of proteins used as anticarcinogenic agents
04/28/2005US20050090000 Novel human 7TM protein and polynucleotides encoding the same
04/28/2005US20050089985 Rescue of canine distemper virus from cdna
04/28/2005US20050089984 Having a specific amino acid sequence, especially fused to a heterologous polypeptide; induces apoptosis
04/28/2005US20050089968 Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin
04/28/2005US20050089957 Chimera; immunoglobuins; antibodies; host cells; immunohistochemistry
04/28/2005US20050089933 Compositions and methods for surrogate antibody modulation of an immune response and transport
04/28/2005US20050089929 Binding native human tissue factor (TF) and does not substantially bind non-native tissue factor; superior anticoagulant activity by binding with high affinity and specificity; reducing cancer cell tissue factor activity and detecting cancer cells that express TF; factor X binding is inhibited
04/28/2005US20050089892 Biiodrugs for diagnosis, drug screening, clinical trial monitoring, treatment of physiological disorders; viral disease and infection prevention; expression vectors
04/28/2005US20050089887 Novel human ion channel proteins
04/28/2005US20050089883 Producing telomerase activators and inhibitors by screening with purified telomerase
04/28/2005US20050089868 Modulators of tissue regeneration
04/28/2005US20050089867 Antigen fragments for the diagnosis of toxoplasma gondii
04/28/2005US20050089866 Identifying modulators for the treatment and prevention of diabetes, pain, obesity, nervous system, inflammatory, cell proliferative and liver disorders
04/28/2005US20050089843 Polyclonal antibody specific for mannose-terminated viral envelope protein for use in detection and prevention of viral diseases
04/28/2005US20050089538 Carcinoembryonic antigen (CEA); administering a humanized Class III, anti-CEA, monoclonal antibody to treat cancer; complementarity-determining regions (CDR) of given amino acid sequences; diagnostic and therapeutic conjugates; transformed cells
04/28/2005US20050089534 Immunogenic rafts, lipid enriched membrane domains, and their use in cancer therapy;tumor protein(-s) and/or glycosphingolipid(-s); vaccine; immunotherapy
04/28/2005US20050089533 Bordetella bronchiseptica p68 antigen and adjuvant; veterinary medicine
04/28/2005US20050089532 Method of protein production using mitochondrial translation system
04/28/2005US20050089531 Two types of foreign genes inserted in such a manner as to allow the expression into two different regions in the recombinant feline herpesvirus type 1 genome
04/28/2005US20050089529 Immunization of dairy cattle with GapC protein against Streptococcus infection
04/28/2005US20050089527 Neisseria meningitidis (Nm) polynucleotides and polypeptides; diagnostic. prophylactic and therapeutic uses
04/28/2005US20050089526 Monomeric unit of the complex containin HIV-1 gp120 and HIV-1 gp41, (ii) the gp4l has one or more mutations in its N-terminal helix, and (iii) the gp120 and gp41 are bound to each other by a disulfide bond between a cysteine residue introduced into the gp120 and a cysteine residue introduced into gp41
04/28/2005US20050089525 Subunit respiratory syncytial virus vaccine preparation
04/28/2005US20050089523 Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids
04/28/2005US20050089521 Methods for treating taxol-induced sensory neuropathy
04/28/2005US20050089520 Antibody stimulating il-ira production
04/28/2005US20050089519 Bispecific anti-cd19x anti-cd16 antibodies and uses thereof
04/28/2005US20050089518 Prospective identification and characterization of breast cancer stem cells
04/28/2005US20050089510 Immunization against plaque forming diseases such as cardiovascular disorders with vaccines for disaggregation
04/28/2005US20050087198 Method for systemic drug delivery through the nail
04/28/2005CA2762955A1 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
04/28/2005CA2545539A1 Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
04/28/2005CA2543447A1 Antibody and use of the same
04/28/2005CA2542691A1 Il-6 antagonist for use as mesothelioma therapeutic agent
04/28/2005CA2542680A1 Pharmaceutical compositions for therapeutic use
04/28/2005CA2542668A1 A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis
04/28/2005CA2542638A1 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
04/28/2005CA2542631A1 Listeria-based epha2 vaccines
04/28/2005CA2542508A1 Novel igg3 antibodies for stimulating phagocytosis
04/28/2005CA2542427A1 Viral fibers
04/28/2005CA2542332A1 Immunomodulating compositions and uses therefor
04/28/2005CA2542327A1 Combination therapy for cancer
04/28/2005CA2542155A1 Poxvirus vector encoding retrovirus (eg hiv) and cytokine
04/28/2005CA2542128A1 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
04/28/2005CA2537900A1 Multiplex vaccines
04/28/2005CA2535043A1 Process for preparing polysaccharide-protein conjugate vaccines
1 ... 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 ... 1823